Human Genome Sciences Inc.
14200 Shady Grove Road
Rockville,
MD 20850-7464
United States - Map
Phone: 301-309-8504
Fax: 301-309-8512
Website: http://www.hgsi.com
Human Genome Sciences, Inc. operates as a biopharmaceutical company in the United States. Its principal products include BENLYSTA for systemic lupus erythematosus; and raxibacumab for inhalation anthrax. The companys mid- and early-stage pipeline products comprise Mapatumumab, a human monoclonal antibody for the treatment of advanced hepatocellular cancer; HGS1036, a biologic for multiple cancers; HGS1029, an IAP inhibitor that is in Phase 1 development to treat patients with solid and lymphoid tumors; and HGS1025, a human monoclonal antibody to the CCR5 receptor that would have entered Phase 1b development in ulcerative colitis. It also holds financial rights to certain products in the GlaxoSmithKline clinical development pipeline, including darapladib, a Phase III clinical trial product for the treatment of coronary heart disease and ischemic stroke; Albiglutide, a biological product for the treatment of type 2 diabetes, which is in Phase III clinical trial stage; and Rilapladib, a small-molecule inhibitor of Lp-PLA2 that is in Phase 2 trial. The company has a license agreement with GlaxoSmithKline for the co-development and co-commercialization of BENLYSTA; and a contract with the Biomedical Advanced Research and Development Authority of the Office of the Assistant Secretary for Preparedness and Response, U.S. Department of Health and Human Services. Human Genome Sciences, Inc. was founded in 1992 and is headquartered in Rockville, Maryland. Key Statistics
| |
| Human Genome Sciences Inc.’s Governance Risk Indicator (GRI®) as of May 1, 2012 is: Audit (Low Concern), Board (Low Concern), Compensation (High Concern), Shareholder Rights (Low Concern). | | Brought to you by Institutional Shareholder Services (ISS) |
| | Pay | Exercised | Mr. H. Thomas Watkins ,
59
Chief Exec. Officer, Pres and Director | 969.00K | 0.00 | Mr. David P. Southwell ,
51
Chief Financial Officer and Exec. VP | 572.00K | 0.00 | Dr. James H. Davis Ph.D., J.D.,
60
Exec. VP, Sec. and Gen. Counsel | 622.00K | 1.34M | Dr. David C. Stump M.D.,
62
Exec. VP of R&D | 647.00K | 0.00 | Mr. Barry A. Labinger ,
48
Chief Commercial Officer and Exec. VP | 590.00K | 1.52M |
|
| | Amounts are as of Dec 30, 2011 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year. | | Currency in USD. |
|
0.60% Nasdaq